ABSTRACT
Background:A surge of mucormycosis during the second wave of COVID intrigued the doctors in India to look for the epidemiology of the illness.Diabetes is the most common risk factor for mucormycosis.COVID can cause hyperglycemia due to various reasons.In this study,we describe the outcome of post COVID mucormycosis with respect to the glycemic status of the patient. (1)To describe the glycemic parameters of patients with COVID-19 Associated M Objectives: ucormycosis.(2)To describe the one month outcome of the patients.(3)To compare patients with Newly Diagnosed Diabetes Mellitus Post COVID-19 and patients having preexisting diabetes mellitus. 75 patients with probable or proven mucormycosis wit Methodology: h history of COVID atleast 2 weeks before were randomly selected from the mucor ward of Rajiv Gandhi Government General Hospital and their glycemic profile assessed.They were followed up for one month and the results were statistically analyzed. Regarding the prior CO Results: VID illness,patients had a median hospital stay of 7 days,received 5 days of intravenous steroids and 3.48 days of supplemental oxygen.Patients who had hyperglycemia during COVID also had statistically significantly higher iv steroid use and higher need for oxygen.There was a statistically very significant(p<0.001) increase in the number of diabetics post COVID(from 57.3% prior to COVID to 90.7% post COVID).Majority of the Mucormycosis patients(69.3%) had severe hyperglycemia during presentation.Pre-existing diabetics had a statistically significant higher incidence of sepsis and renal failure during treatment for mucormycosis.Otherwise,there was no significant difference in outcome between various grades of severity of hyperglycemia,and no distinction was found between pre-existing diabetics and newly diagnosed diabetics